Targeting LRRC15 expressing fibroblasts holds therapeutic potential to ameliorate inflammation and fibrosis in autoimmune diseases
Clicks: 1
ID: 318535
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #172 of 202 articles by views in Lara D. Veeken
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 202 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
OBJECTIVES: Targeting stromal cells such as inflammatory fibroblasts presents a potential avenue to alleviate autoimmune inflammation and fibrosis. This study aimed to characterize LRRC15 expression in Rheumatoid Arthritis (RA) and Systemic Sclerosis (SSc) across fibroblast subsets and assess whether targeting LRRC15 expressing fibroblasts can be beneficial for the treatment of fibrosis and fibroblast-mediated inflammation. METHODS: We conducted transcriptomic analyses of Lrrc15 in bulk and single-cell RNA-seq datasets from RA and SSc. We used flow cytometry, RNA-seq, immunohistochemistry and spatial transcriptomics to define Lrrc15 expression patterns in diseased tissues. We performed in vitro and in vivo assays to elucidate the function of LRRC15 in inflammatory fibroblasts. RESULTS: When compared with healthy controls, we observed a higher activated fibroblast gene signature in RA synovium and SSc skin biopsies that correlated with Lrrc15 expression. Multi-IF imaging highlighted the clustering of LRRC15 expressing fibroblasts within tertiary lymphoid structures (TLS) in RA synovium. Knock down of Lrrc15 in primary cells reduced production of TNF-α induced inflammatory chemokines including CCL3 and CXCL10. We confirmed LRRC15 upregulation in mouse models of wound healing and pulmonary fibrosis. Inflammatory fibroblasts with high LRRC15 expression were susceptible to NK cell-mediated LRRC15 specific lysis in vitro. CONCLUSION: Targeting LRRC15+ fibroblasts and fibrotic microenvironment may offer a new therapeutic opportunity to reduce inflammation in RA, SSc and other autoimmune disorders where activated fibroblasts play a role in disease pathogenesis.
| Reference Key |
openalex_W7165762680
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Xintao Tu, Thao-Nguyen Bach, Arjun Baghela, Mark Ziestorff, William Smallridge, Qian Chen, Soha Motlagh, Travis Barr, Marc Sze, In Sock Jang, Jie Zhang-Hoover, Alex Tamburino, Vanessa Peterson, Rajesh Kamath, Marc C. Levesque, Karin Vroom, Nidhi Malhotra |
| Journal | Lara D. Veeken |
| Year | 2026 |
| DOI |
10.1093/rheumatology/keag293
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.